EUVIMEDEUVIMED entdecken
Multizentrische Studie

Survival rates of systemic interventions for psoriasis in the Western Japan Psoriasis Registry: A multicenter retrospective study

Tetsuji Yanase iD, Noriko Tsuruta iD, Kazuki Yamaguchi, Chika Ohata iD, Bungo Ohyama, Eri Katayama, Kazunari Sugita, Maki Kuwashiro, Aki Hashimoto, Kentaro Yonekura iD, Yuko Higashi iD, Hiroyuki Murota iD und 20 weitere

The Journal of Dermatology · 2023-06 · 50 (6) · 753-765

DOI: 10.1111/1346-8138.16737 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Journal of Dermatology, online erschienen am 14.02.2023. Verfasst von Tetsuji Yanase und 31 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Hiroshima City North Medical Center Asa Citizens Hospital, Hiroshima, Japan. Hauptthemen laut MEDLINE: Arthritis, Psoriatic, Psoriasis, Biological Products. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: AbbVie, Amgen, Eisai.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Psoriasis affects approximately 0.3% of the Japanese population. Recently, various effective systemic drugs have become available, and the continuation of a given treatment has become critical because of the chronic nature of psoriasis. Factors affecting drug survival (the time until treatment discontinuation) in psoriasis treatment include efficacy, safety, ease of use, and patient preference. In the present study, the authors retrospectively surveyed a multifacility patient registry to determine the real‐world evidence of the survival rate of systemic interventions for psoriasis treatment. Patients with psoriasis who visited 20 facilities in the Western Japan area between January 2019 and May 2020 and gave written consent were registered as study participants, and their medical history of systemic interventions for psoriasis (starting from 2010) was retrospectively collected and analyzed. The drugs investigated were adalimumab, infliximab, ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, cyclosporine, and apremilast. When drugs were discontinued, the reasons were also recorded. A total of 1003 patients with psoriasis including 268 with psoriatic arthritis (PsA) were enrolled. In biologics, more recently released drugs such as interleukin 17 inhibitors showed a numerically higher survival rate in the overall (post‐2010) analysis. However, in the subset of patients who began treatment after 2017, the difference in the survival rate among the drugs was smaller. The reasons for discontinuing drugs varied, but a loss of efficacy against dermatological or joint symptoms were relatively frequently seen with some biologics and cyclosporine. The stratification of drug survival rates based on patient characteristics such as bio‐naive or experienced, normal weight or obese, and with or without PsA, revealed that bio‐experienced, obese, and PsA groups had poorer survival rates for most drugs. No notable safety issues were identified in this study. Overall, the present study revealed that the biologics show differences in their tendency to develop a loss of efficacy, and the factors that negatively impact the survival rate of biologics include the previous use of biologics, obesity, and PsA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, PsoriaticPsoriasisBiological ProductsHumansRetrospective StudiesSurvival RateJapanCyclosporineRegistries

Stichwörter der Autor:innen

Japanbio-naivebiologicsdrug survivalobesitypsoriasispsoriatic arthritissystemic intervention

Substanzen

Biological ProductsCyclosporine

Autor:innen und Institutionen

  • Department of Dermatology, Hiroshima City North Medical Center Asa Citizens Hospital, Hiroshima, Japan.
  • Department of Dermatology, Fukuoka University Faculty of Medicine, Fukuoka, Japan.
  • Department of Dermatology, Kitakyuhsu City Yahata Hospital, Kitakyushu, Japan.
  • Department of Dermatology, Saiseikai Futsukaichi Hospital, Fukuoka, Japan.
  • Department of Dermatology, Kurume University School of Medicine, Kurume, Japan.
  • Department of Dermatology, Osaka General Medical Center, Osaka, Japan.

ORCID-Profile: Tetsuji Yanase, Noriko Tsuruta, Chika Ohata, Kentaro Yonekura, Yuko Higashi, Hiroyuki Murota, Yuta Koike, Yutaka Hatano, Takuya Miyagi, Sakae Kaneko, Masataka Ota, Shin Morizane, Kenta Ikeda, Takeshi Nakahara, Natsuko Sasaki, Etsuko Okada, Shinichi Imafuku

Förderung

  • AbbVie
  • Amgen
  • Eisai
  • KyowaKirin
  • Maruho
  • Sunpharma
  • Taiho Yakuhin Kogyo

Zitieren

APA

Yanase, T., Tsuruta, N., Yamaguchi, K., Ohata, C., Ohyama, B., Katayama, E., Sugita, K., Kuwashiro, M., Hashimoto, A., Yonekura, K., Higashi, Y., Murota, H., Koike, Y., Matsuzaka, Y., Kikuchi, S., Hatano, Y., Saito, K., Takahashi, K., Miyagi, T., …, & Imafuku, S. (2023). Survival rates of systemic interventions for psoriasis in the Western Japan Psoriasis Registry: A multicenter retrospective study. The Journal of Dermatology, 50(6), 753-765. https://doi.org/10.1111/1346-8138.16737

Vancouver

Yanase T, Tsuruta N, Yamaguchi K, Ohata C, Ohyama B, Katayama E, et al. Survival rates of systemic interventions for psoriasis in the Western Japan Psoriasis Registry: A multicenter retrospective study. The Journal of Dermatology. 2023;50(6):753-765. doi:10.1111/1346-8138.16737

BibTeX
@article{Yanase2023,
  author = {Yanase, Tetsuji and Tsuruta, Noriko and Yamaguchi, Kazuki and Ohata, Chika and Ohyama, Bungo and Katayama, Eri and Sugita, Kazunari and Kuwashiro, Maki and Hashimoto, Aki and Yonekura, Kentaro and Higashi, Yuko and Murota, Hiroyuki and Koike, Yuta and Matsuzaka, Yuki and Kikuchi, Satoko and Hatano, Yutaka and Saito, Kanami and Takahashi, Kenzo and Miyagi, Takuya and Kaneko, Sakae and Ota, Masataka and Harada, Kayo and Morizane, Shin and Ikeda, Kenta and Furue, Masutaka and Nakahara, Takeshi and Okazaki, Fusako and Sasaki, Natsuko and Okada, Etsuko and Yoshida, Yuichi and Ito, Kotaro and Imafuku, Shinichi},
  title = {Survival rates of systemic interventions for psoriasis in the Western Japan Psoriasis Registry: A multicenter retrospective study},
  journal = {The Journal of Dermatology},
  year = {2023},
  volume = {50},
  number = {6},
  pages = {753--765},
  doi = {10.1111/1346-8138.16737}
}
Kostenlos starten →